Related Experiment Video
Updated: May 28, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
A possible anticancer agent, type III interferon, activates cell death pathways and produces antitumor effects
Masatoshi Tagawa1, Kiyoko Kawamura, Quanhai Li
1Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuo-ku, Chiba 260-8717, Japan. mtagawa@chiba-cc.jp
Clinical & Developmental Immunology
|October 21, 2011
Summary
Type III interferons (IFNs), also known as IFN-λs, show promise as anticancer agents due to their tumor cell-killing abilities and limited effects on normal cells. They offer a potential alternative to type I IFNs, which have significant side effects.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Background:
- Type I interferons (IFNs), such as IFN-α/β, have been used in cancer treatment for decades but are limited by adverse effects.
- Type III IFNs (IFN-λs) represent a novel class with distinct properties.
- Understanding IFN-λs' role in cancer is crucial for developing new therapies.
Purpose of the Study:
- To summarize current knowledge on IFN-λ-mediated tumor cell death.
- To compare the anti-cancer properties of type III IFNs with type I IFNs.
- To explore the potential of IFN-λs as anticancer agents.
Main Methods:
- Review of existing literature on type I and type III interferons.
- Analysis of signaling pathways and receptor expression patterns.
- Comparison of cytotoxicity profiles in tumor versus normal cells.
Main Results:
- Type III IFNs inhibit tumor cell proliferation via cell cycle arrest and apoptosis.
- Restricted expression of the type III IFN receptor suggests lower toxicity to normal cells compared to type I IFNs.
- IFN-λs share signaling pathways with type I IFNs but exhibit distinct biological activities.
Conclusions:
- Type III IFNs demonstrate potential as targeted anticancer agents with a favorable safety profile.
- The distinct receptor expression of IFN-λs may explain their limited impact on healthy tissues.
- Further research into IFN-λs could lead to novel cancer treatment strategies.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...